4 Repeat Tauopathy Neuroimaging Initiative (4RTNI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01804452 |
Recruitment Status
:
Active, not recruiting
First Posted
: March 5, 2013
Last Update Posted
: May 8, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Progressive Supranuclear Palsy Corticobasal Degeneration | Other: Observational Study |
Study Type : | Observational |
Actual Enrollment : | 110 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration |
Study Start Date : | January 2011 |
Estimated Primary Completion Date : | October 2017 |
Estimated Study Completion Date : | December 2017 |

Group/Cohort | Intervention/treatment |
---|---|
Subjects with a diagnosis of PSP or CBD | Other: Observational Study |
- Progressive Supranuclear Palsy Rating Scale [ Time Frame: Baseline, 6 months and 1 year ]Change from baseline
- Eye movement function [ Time Frame: Baseline, 6 months and 1 year ]Change from baseline
- Brain volume on MRI [ Time Frame: Baseline, 6 months and 1 year ]Change from baseline.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 90 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Clinical diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration
- Must have a reliable study partner who has frequent contact with the subject
- Willing and able to undergo testing procedures
Exclusion Criteria:
- Significant neurological disease other than PSP or CBD
- Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01804452
United States, California | |
University of California, San Francisco | |
San Francisco, California, United States, 94158 |
Principal Investigator: | Adam Boxer, MD, PhD | University of California, San Francisco |
Publications:
Responsible Party: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT01804452 History of Changes |
Other Study ID Numbers: |
4RTNI R01AG031278 ( U.S. NIH Grant/Contract ) |
First Posted: | March 5, 2013 Key Record Dates |
Last Update Posted: | May 8, 2017 |
Last Verified: | May 2017 |
Keywords provided by University of California, San Francisco:
Progressive Supranuclear Palsy Corticobasal Degeneration Biomarker Neuroimaging |
MRI Tau Oculomotor |
Additional relevant MeSH terms:
Supranuclear Palsy, Progressive Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Ophthalmoplegia Ocular Motility Disorders |
Cranial Nerve Diseases Tauopathies Neurodegenerative Diseases Paralysis Neurologic Manifestations Eye Diseases Signs and Symptoms |